Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Mapula

Plastic and Reconstructive Surgery Fort Worth, TX Medical Doctor

NPI 1861623704 CMS profile 129643

909 9Th Ave Ste 204, Fort Worth, TX 76104

Open in the dashboard

General payments

$14,233

180 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$220,181 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Steven Mapula of Fort Worth, TX is reported in the CMS Open Payments database as having received $14,233 across 180 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $220,181 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,442 71
2024 General $4,755 50
2023 General $1,559 32
2022 General $670 13
2021 General $98 3
2020 General $263 3
2019 General $445 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Mapula
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Steven Mapula were reported at $6,442. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Steven Mapula Plastic and Reconstructive Surgery median Middle half National median
2019 $445 $335 $121–$1,264 $163
2020 $263 $162 $57–$417 $114
2021 $98 $245 $89–$735 $132
2022 $670 $325 $120–$932 $149
2023 $1,559 $343 $129–$999 $160
2024 $4,755 $390 $141–$1,085 $164
2025 $6,442 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $5,831 51 payments
  2. Ethicon US, LLC $3,196 11 payments
  3. TELA Bio, Inc. $1,323 39 payments
  4. Musculoskeletal Transplant Foundation Inc. $844 8 payments
  5. Integra LifeSciences Corporation $703 21 payments
  6. Allergan Inc. $470 5 payments
  7. Davol Inc. $254 3 payments
  8. Avita Medical Americas, LLC $247 4 payments
  9. Acera Surgical, Inc. $182 6 payments
  10. Sientra, Inc. $180 2 payments
  11. Other $1,003 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,416 176 payments
  2. Consulting Fee $2,450 1 payment
  3. Travel and Lodging $2,366 3 payments
Products named General payments · program years 2019–2025
  1. NATRELLE SALINE-FILLED BREAST IMPLANTS $6,573 44 payments
  2. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $2,384 9 payments
  3. REVOLVE $2,253 8 payments
  4. ALLODERM $1,030 11 payments
  5. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $953 28 payments
  6. STRATAFIX $640 8 payments
  7. INTEGRA DERMAL REGENERATION TEMPLATE $633 19 payments
  8. Integra Recon-Skin And Wound $600 17 payments
  9. Integra Recon-Skin And Wound $600 17 payments
  10. PRIMATRIX $451 11 payments
  11. Other $5,603 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

156

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$3,613

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

48.1%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 43 $2,089
Gabapentin Generic 24 $573
Ondansetron Odt Ondansetron Brand 41 $490
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 34 $406
Tramadol Hcl Generic 14 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$38,850

Medicare's payments for the services billed

Medicare patients

36

Average age 67

Services billed

175

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Depression 56%
Diabetes 44%
Cancer 36%
Ischemic heart disease 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record